This announcement is a separate document:
京新药业:2024年半年度报告摘要
Zhejiang Jingxin Pharmaceutical: Summary of Half-Year Report in 2024.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Related Stocks Related Stocks
Latest
15:59
Yujingguang's sales revenue in November was 2.03 billion New Taiwan Dollars, a year-on-year decrease of 18.3%.
15:58
Bank of America: For the week ending Wednesday, the inflow of cash reached 136.4 billion dollars; this is the largest weekly inflow since March 2023. Inflows into stocks amounted to 8.2 billion dollars, bonds inflow was 4.9 billion dollars, and inflow into cryptos was 3 billion dollars. The inflow of funds into cryptos over the past four weeks reached 11 billion dollars, setting an all-time record.
BAC+1.36%
15:54
In its first month of sales, the Aion RT broke 10,000 units, setting a new record for monthly sales of new energy sedans.
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.